Market analysis reports from reputable firms

Ipsen and Genfit's Iqirvo Receives Accelerated FDA Approval for Rare Liver Disease After Eight Years

Jun 10, 2024, 10:45 PM

Ipsen and Genfit have received accelerated approval from the U.S. Food and Drug Administration (FDA) for their new drug, Iqirvo, which treats primary biliary cholangitis, a rare chronic inflammatory liver disease. This marks the first new treatment option for the disease in eight years. The approval sets the stage for a potential market competition with Intercept Pharmaceuticals.